- 联合国称艾滋病新疫苗为抗艾带来新希望
2009年09月25日 08:44 来源：中国新闻网
视频：艾滋病疫苗研制获重大进展 可降低感染率31% 来源：中央电视台-朝闻天下
中新网9月25日电 两个联合国机构24日表示，在泰国试验的艾滋病疫苗结果，为抗击艾滋病活动带来了“新希望”，但仍需进行更多工作，以观察其是否可在其它地区推广。
据路透社报道，这种疫苗混合了赛诺菲巴斯德生产的ALVAC金丝雀痘疫苗和失败的AIDSVAX疫苗，后者由旧金山一家名为VaxGen的公司研制而成，现在由非营利性组织“全球传染病解决协会”(Global Solutions for Infectious)所拥有。
世界卫生组织和联合国艾滋病规划署表示：“研究结果是重大的科学进步，首次证明疫苗可以阻止成人群体感染艾滋病，具有重要意义。”
来自美国和泰国政府机构的研究者称，共有1.6万名泰国异性恋志愿者接受试验，他们没有感染艾滋病的特别风险。试验结果显示，疫苗使他们感染艾滋病的风险减少了32%。
|
|
这两个联合国机构在联合声明中称，疫苗“有一定的保护作用”。
两机构表示，“研究成果为艾滋病疫苗研究领域注入了新希望，预示一种安全和高效的艾滋病疫苗，可能会被全世界最需要它的人得到。”
“该疫苗中的两种具体疫苗成分是否适用于世界其它地区，适用于不同基因，不同艾滋病亚型的人群，还有待观察。”
泰国称艾滋病疫苗获重大突破 可降1/3感染风险
2009年09月25日09:04
来源：中国日报网 中国日报网环球在线消息：艾滋病被称为世纪绝症，联合国艾滋病规划署（UNAIDS）提供的数据显示，全球每天新感染艾滋病病毒（HIV）的人高达7500人，仅2007年就有200万人死于艾滋病。多年来人类一直不懈地寻找对抗艾滋病的良方，但是有效的防治药物仍然缺乏。
泰国公共卫生部9月24日在曼谷宣布，预防艾滋病疫苗已经取得重大突破，一种联合疫苗首次经试验证实可以将感染爱滋病的风险降低三分之一。
神奇的联合疫苗
据美国媒体报道，泰国公共卫生部进行的这项耗资1.05亿美元的试验项目由美国陆军和美国国家过敏症和传染病研究所资助，同时得到了泰国政府的大力支持。这次试验是世界最大规模的艾滋病疫苗试验之一，泰国16000多名志愿者参与了试验，他（她）们的年龄从18岁到30岁，都是异性恋人士，即感染艾滋病的风险属平均范围。
研究人员试验的是一种以“prime-boost”方式进行联合免疫的预防艾滋病毒疫苗。也就是说，这种联合疫苗结合了两种已有的疫苗，一种是由法国Sanofi-Pasteur公司开发的ALVAC疫苗，另一种是由洛杉矶VaxGen公司研发的AIDSVAX疫苗。
研究人员表示，这两个疫苗在之前分开进行的独立试验中都不能有效预防HIV。但是令人惊喜的是，它们结合在一起竟然产生不可思议的效果。第一种疫苗使人体免疫系统做好攻击HIV的准备，第二种疫苗在此基础上会进一步加强效力。
在试验中，研究人员把这些HIV呈阴性（即没有感染艾滋病毒）的志愿者分成两组，在6个月中为一半人接种了4次ALVAC疫苗和2次AIDSVAX疫苗，另一半人也接种了疫苗，但不是真的试验疫苗，志愿者们在试验结束前都不知道自己接种的是什么疫苗。
随后，研究人员对志愿者们进行了长达3年的跟踪调查。研究人员给所有参与者都发放了避孕套并提供咨询服务，同时为那些有性传播疾病的人提供治疗。每6个月研究人员就会对所有人员进行一次检查以确定是否感染HIV。如果有人感染上艾滋病毒，研究人员则用抗病毒药物免费给予治疗。
最终的试验结果显示，8197名接种了联合疫苗的人中有51人新感染HIV，而8198名没有真正接种疫苗的人中有74人感染，也就是说，接种疫苗的人群感染艾滋病的风险比没有接种的人群降低了31%。
泰国公共卫生部部长维特哈雅在曼谷举行的新闻发布会上说：“这是一个重大科学突破。人类首次有证据证明HIV疫苗有预防感染的效力。”该项目美国陆军方面的负责人杰罗姆·金上校接受电话采访时也表示，虽然这个疫苗的作用有限，但“这是我们拥有一个安全有效的预防疫苗的第一个证据”。
有待进一步研究
但是，研究人员表示，这种联合疫苗对已经感染HIV的人没有效果，这也是研究人员的另一个研究目标，即检测这种疫苗能否抑制艾滋病毒对人体免疫系统的损害以及阻止已感染HIV的患者病情加重。
此外，这项试验在泰国进行并使用了泰国常见的HIV毒株，因此目前还不清楚这种疫苗对美国、非洲或者世界其他地方的HIV毒株是否起作用。
研究人员还表示，联合疫苗还需要进一步研究测试，他们想知道：它的保护作用能持续多久，是否需要增加效力更强的加强疫苗，是否它能帮助男同性恋和注射吸毒者预防感染HIV。
据悉，这次试验的详细内容将于10月在巴黎举行的一个有关疫苗的会议上公布。
|
|
神奇的联合疫苗
据美国媒体报道，泰国公共卫生部进行的这项耗资1.05亿美元的试验项目由美国陆军和美国国家过敏症和传染病研究所资助，同时得到了泰国政府的大力支持。这次试验是世界最大规模的艾滋病疫苗试验之一，泰国16000多名志愿者参与了试验，他（她）们的年龄从18岁到30岁，都是异性恋人士，即感染艾滋病的风险属平均范围。
研究人员试验的是一种以“prime-boost”方式进行联合免疫的预防艾滋病毒疫苗。也就是说，这种联合疫苗结合了两种已有的疫苗，一种是由法国Sanofi-Pasteur公司开发的ALVAC疫苗，另一种是由洛杉矶VaxGen公司研发的AIDSVAX疫苗。
研究人员表示，这两个疫苗在之前分开进行的独立试验中都不能有效预防HIV。但是令人惊喜的是，它们结合在一起竟然产生不可思议的效果。第一种疫苗使人体免疫系统做好攻击HIV的准备，第二种疫苗在此基础上会进一步加强效力。
在试验中，研究人员把这些HIV呈阴性（即没有感染艾滋病毒）的志愿者分成两组，在6个月中为一半人接种了4次ALVAC疫苗和2次AIDSVAX疫苗，另一半人也接种了疫苗，但不是真的试验疫苗，志愿者们在试验结束前都不知道自己接种的是什么疫苗。
随后，研究人员对志愿者们进行了长达3年的跟踪调查。研究人员给所有参与者都发放了避孕套并提供咨询服务，同时为那些有性传播疾病的人提供治疗。每6个月研究人员就会对所有人员进行一次检查以确定是否感染HIV。如果有人感染上艾滋病毒，研究人员则用抗病毒药物免费给予治疗。
最终的试验结果显示，8197名接种了联合疫苗的人中有51人新感染HIV，而8198名没有真正接种疫苗的人中有74人感染，也就是说，接种疫苗的人群感染艾滋病的风险比没有接种的人群降低了31%。
泰国公共卫生部部长维特哈雅在曼谷举行的新闻发布会上说：“这是一个重大科学突破。人类首次有证据证明HIV疫苗有预防感染的效力。”该项目美国陆军方面的负责人杰罗姆·金上校接受电话采访时也表示，虽然这个疫苗的作用有限，但“这是我们拥有一个安全有效的预防疫苗的第一个证据”。
有待进一步研究
但是，研究人员表示，这种联合疫苗对已经感染HIV的人没有效果，这也是研究人员的另一个研究目标，即检测这种疫苗能否抑制艾滋病毒对人体免疫系统的损害以及阻止已感染HIV的患者病情加重。
此外，这项试验在泰国进行并使用了泰国常见的HIV毒株，因此目前还不清楚这种疫苗对美国、非洲或者世界其他地方的HIV毒株是否起作用。
研究人员还表示，联合疫苗还需要进一步研究测试，他们想知道：它的保护作用能持续多久，是否需要增加效力更强的加强疫苗，是否它能帮助男同性恋和注射吸毒者预防感染HIV。
据悉，这次试验的详细内容将于10月在巴黎举行的一个有关疫苗的会议上公布。
(责任编辑：罗园)
The United Nations said the new vaccine for HIV-AIDS has brought new hope
At 08:44 on September 25, 2009 Source: China News Net
Video: HIV vaccine development have been significant advances can reduce the infection rate 31% Source: China Central Television - Chao-Wen world
BEIJING, September 25 Xinhua 24, two UN agencies said that in the results of an AIDS vaccine trial in Thailand, in order to fight AIDS has brought "new hope", but more work remains to be done to see whether it can be other parts of the promotion.
According to Reuters, a mixture of this vaccine produced by Sanofi Pasteur ALVAC canarypox vaccine and the failure of AIDSVAX vaccine, which by the San Francisco company called VaxGen made the company developed, and now by the non-profit organization "Global Infectious Diseases to solve the Association" (Global Solutions for Infectious) owned.
World Health Organization and UNAIDS, said: "The findings are significant scientific advances for the first time that the vaccine can prevent HIV-infected adult population is of great significance."
Government agencies from the United States and Thailand, the researchers said, a total of 16000 Thailand, heterosexual volunteers test they do not have special risk of HIV infection. The results showed that the vaccine so that they reduce the risk of HIV infection by 32%.
The two UN agencies said in a joint statement, the vaccine "has a certain protective effect."
The two institutions, "said research for AIDS vaccine research is injecting new hope, herald a safe and effective AIDS vaccine may be the world's most those who need it to be."
"The vaccine in the two specific vaccine composition is applicable to rest of the world, for different genes, different subtypes of the AIDS population, remains to be seen."
Thailand said that a major breakthrough in AIDS vaccine may be reduced by 1 / 3 the risk of infection
At 09:04 on September 25, 2009
Source: China Daily Network
China News Network International Online News: AIDS is an incurable disease known as the century, the United Nations AIDS Program (UNAIDS) to provide the data show that newly infected with HIV worldwide every day (HIV) as many as 7,500 people, only 2 million people in 2007 alone died of AIDS. Over the years mankind has been working tirelessly to find the recipe for the fight against AIDS, but it is still a lack of effective prevention and treatment drug.
Ministry of Public Health of Thailand in Bangkok on September 24 announced that the prevention of an AIDS vaccine has been a major breakthrough, a vaccine for the first time can be confirmed by the tests reduce the risk of AIDS infection in third.
The magic combination vaccine
According to U.S. media reports, the Thai Ministry of Public Health to conduct a cost of 105 million U.S. dollars this pilot project by the U.S. Army and the National Institute of Allergy and Infectious Diseases funded the same time, the Government of Thailand has been strongly supported. The test is the world's largest HIV vaccine trial, one of Thailand's more than 16,000 volunteers participated in the pilot, he (she) their ages ranged from 18 to 30 years old, are heterosexual people, that is the risk of HIV infection is the average range.
The researchers test is a kind of "prime-boost" approach to co-immunization vaccines for HIV prevention. In other words, this combined vaccine has been a combination of two kinds of vaccines, one is by the French Sanofi-Pasteur's ALVAC vaccine, developed, and the other one is from the Los Angeles AIDSVAX vaccine developed by VaxGen Inc..
The researchers said that this vaccine in the previous two separate independent experiments can not be effective in preventing HIV. But the pleasant surprise is that they actually produce incredible combination of results. The first vaccine to HIV attacks the body's immune system do a good job of preparation, the second vaccination on this basis will further improve effectiveness.
In the study, the researchers of these HIV-negative (ie not infected with HIV) of the volunteers were divided into two groups, at 6 months for half of the population has been immunized four times ALVAC vaccine and 2 AIDSVAX vaccine, the other half of people are vaccinated of the vaccine, but not really test vaccines before the end of the trial volunteers do not know what the vaccine inoculation.
Subsequently, the researchers volunteers for as long as three years of follow-up investigation. The researchers distributed to all participants of condoms and the provision of advisory services, while for those with sexual transmitted diseases, provide treatment. Every 6 months, the researchers will conduct an inspection of all personnel to determine whether infection of HIV. If someone infected with HIV, researchers are using antiviral drugs for free treatment.
The final results showed that 8197 persons vaccinated with combined vaccine, 51 were newly infected with HIV, while the 8198 did not really vaccinated people, 74 people are infected, that is, people vaccinated the risk of HIV infection than the people are not immunized to reduce by 31%.
Thai Public Health Minister Weitehaya at a news conference in Bangkok said: "This is a significant scientific breakthroughs. There is evidence of man's first HIV vaccine to prevent infection of the effect." Aspects of the project person in charge of the U.S. Army Colonel Jerome Kim a telephone interview, also said that while the role of this vaccine is limited, but "it is we have a safe and effective vaccine to prevent the first evidence."
Further study
However, the researchers said that such a combined vaccine for people already infected with HIV has no effect, this is another study researchers goal, which is testing the vaccine could inhibit HIV virus damages the immune system, as well as to prevent infected with HIV patients sicker.
In addition, the experiment carried out in Thailand and the use of the HIV strains common in Thailand, it is still not clear whether this vaccine to the United States, Africa or elsewhere in the world whether the HIV strains play a role.
The researchers also said the vaccine still require further research and testing, they want to know: it's protective effect can last long, the need to increase the effectiveness of the strengthening of a stronger vaccine, if it helps gay men and injecting drug users, prevention of infection HIV.
It is reported that the details of this test will be held in Paris in October a public meeting on the vaccine.
(Editor: Luo Park)
At 08:44 on September 25, 2009 Source: China News Net
Video: HIV vaccine development have been significant advances can reduce the infection rate 31% Source: China Central Television - Chao-Wen world
BEIJING, September 25 Xinhua 24, two UN agencies said that in the results of an AIDS vaccine trial in Thailand, in order to fight AIDS has brought "new hope", but more work remains to be done to see whether it can be other parts of the promotion.
According to Reuters, a mixture of this vaccine produced by Sanofi Pasteur ALVAC canarypox vaccine and the failure of AIDSVAX vaccine, which by the San Francisco company called VaxGen made the company developed, and now by the non-profit organization "Global Infectious Diseases to solve the Association" (Global Solutions for Infectious) owned.
World Health Organization and UNAIDS, said: "The findings are significant scientific advances for the first time that the vaccine can prevent HIV-infected adult population is of great significance."
Government agencies from the United States and Thailand, the researchers said, a total of 16000 Thailand, heterosexual volunteers test they do not have special risk of HIV infection. The results showed that the vaccine so that they reduce the risk of HIV infection by 32%.
The two UN agencies said in a joint statement, the vaccine "has a certain protective effect."
The two institutions, "said research for AIDS vaccine research is injecting new hope, herald a safe and effective AIDS vaccine may be the world's most those who need it to be."
"The vaccine in the two specific vaccine composition is applicable to rest of the world, for different genes, different subtypes of the AIDS population, remains to be seen."
Thailand said that a major breakthrough in AIDS vaccine may be reduced by 1 / 3 the risk of infection
At 09:04 on September 25, 2009
Source: China Daily Network
China News Network International Online News: AIDS is an incurable disease known as the century, the United Nations AIDS Program (UNAIDS) to provide the data show that newly infected with HIV worldwide every day (HIV) as many as 7,500 people, only 2 million people in 2007 alone died of AIDS. Over the years mankind has been working tirelessly to find the recipe for the fight against AIDS, but it is still a lack of effective prevention and treatment drug.
Ministry of Public Health of Thailand in Bangkok on September 24 announced that the prevention of an AIDS vaccine has been a major breakthrough, a vaccine for the first time can be confirmed by the tests reduce the risk of AIDS infection in third.
The magic combination vaccine
According to U.S. media reports, the Thai Ministry of Public Health to conduct a cost of 105 million U.S. dollars this pilot project by the U.S. Army and the National Institute of Allergy and Infectious Diseases funded the same time, the Government of Thailand has been strongly supported. The test is the world's largest HIV vaccine trial, one of Thailand's more than 16,000 volunteers participated in the pilot, he (she) their ages ranged from 18 to 30 years old, are heterosexual people, that is the risk of HIV infection is the average range.
The researchers test is a kind of "prime-boost" approach to co-immunization vaccines for HIV prevention. In other words, this combined vaccine has been a combination of two kinds of vaccines, one is by the French Sanofi-Pasteur's ALVAC vaccine, developed, and the other one is from the Los Angeles AIDSVAX vaccine developed by VaxGen Inc..
The researchers said that this vaccine in the previous two separate independent experiments can not be effective in preventing HIV. But the pleasant surprise is that they actually produce incredible combination of results. The first vaccine to HIV attacks the body's immune system do a good job of preparation, the second vaccination on this basis will further improve effectiveness.
In the study, the researchers of these HIV-negative (ie not infected with HIV) of the volunteers were divided into two groups, at 6 months for half of the population has been immunized four times ALVAC vaccine and 2 AIDSVAX vaccine, the other half of people are vaccinated of the vaccine, but not really test vaccines before the end of the trial volunteers do not know what the vaccine inoculation.
Subsequently, the researchers volunteers for as long as three years of follow-up investigation. The researchers distributed to all participants of condoms and the provision of advisory services, while for those with sexual transmitted diseases, provide treatment. Every 6 months, the researchers will conduct an inspection of all personnel to determine whether infection of HIV. If someone infected with HIV, researchers are using antiviral drugs for free treatment.
The final results showed that 8197 persons vaccinated with combined vaccine, 51 were newly infected with HIV, while the 8198 did not really vaccinated people, 74 people are infected, that is, people vaccinated the risk of HIV infection than the people are not immunized to reduce by 31%.
Thai Public Health Minister Weitehaya at a news conference in Bangkok said: "This is a significant scientific breakthroughs. There is evidence of man's first HIV vaccine to prevent infection of the effect." Aspects of the project person in charge of the U.S. Army Colonel Jerome Kim a telephone interview, also said that while the role of this vaccine is limited, but "it is we have a safe and effective vaccine to prevent the first evidence."
Further study
However, the researchers said that such a combined vaccine for people already infected with HIV has no effect, this is another study researchers goal, which is testing the vaccine could inhibit HIV virus damages the immune system, as well as to prevent infected with HIV patients sicker.
In addition, the experiment carried out in Thailand and the use of the HIV strains common in Thailand, it is still not clear whether this vaccine to the United States, Africa or elsewhere in the world whether the HIV strains play a role.
The researchers also said the vaccine still require further research and testing, they want to know: it's protective effect can last long, the need to increase the effectiveness of the strengthening of a stronger vaccine, if it helps gay men and injecting drug users, prevention of infection HIV.
It is reported that the details of this test will be held in Paris in October a public meeting on the vaccine.
(Editor: Luo Park)
艾滋病或不再是绝症
鸡尾酒疗法并非万能，抗药性与毒副作用导致联合疗法与中药疗法应用的迫切性
从食品植物研究开发的治疗艾滋病新药三合皂甙〔康生丹四代〕介绍
专家：艾滋病早治疗能多活30年以上“隐形”感染者进入晚期才被确诊
T细胞、T细胞亚群、 调节性（或抑制性）T细胞在艾滋病康复中的研究
康生丹颗粒〈ksd〉对免疫抑制模型小鼠免疫功能影响实验研究-公布